Mesa Laboratories Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$259.2Mnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q2 Fiscal Year 2027 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Growth Quarterly3.4%Target: Low to mid-single digit organic growth
Adjusted Operating Income (AOI) Margin (excluding unusual items) Quarterly25.5%Target: Mid-20s percentage range
Total Net Leverage Ratio Quarterly2.1xTarget: Continued deleveraging below 2.0x
Free Cash Flow Annually39.6MTarget: Maximize cash conversion for debt paydown
Watch Items
- CEO Transition Execution under Dr. Siddhartha KadiaTrigger: Departure from strategic plan or disruption in commercial executionAction: Evaluate management stability and operational continuity
- Clinical Genomics China Market ContractionTrigger: China revenue falling below 5% of segment total or further regulatory headwindsAction: Assess geographic diversification efforts and non-China growth acceleration
- Biopharmaceutical Development Division RecoveryTrigger: Continued organic revenue decline (FY26 was -0.2% and 4Q26 was -29.9%)Action: Review commercial execution and export-control shipping delays
Research as of 19 Jun 2026